CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Concord Drugs Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Concord Drugs Ltd
Survey No: 249, Brahmanapally(V), Hayath
Phone: +91 9052779505p:+91 9052779505 HYDERABAD, 501511  India Ticker: 538965538965
Business Summary
Concord Drugs Limited is an India-based pharmaceutical company. The Company's principal activity is to manufacture licensed drugs based on the formulations approved. The Company is focused on developing drug delivery systems, including multiple unit pellet system (MUPS), sustained release, and modified release pellets. It operates a Current Good Manufacturing Practice (cGMP) contract manufacturing formulation-fill-finish facility, offering a full spectrum of pharmaceutical development and manufacturing services for drug products. The Company's products include pharmaceutical ready to fill pellets, MUPS; tissue bio adhesive; injectables (small volume parenterals); oral solid dosages (tablets); oral solid dosages (capsules); liquid orals, and dry syrup (powder). It also offers hand sanitizers under the brand name, PROTON SAFE. It manufactures hand sanitizers on third party basis also. The Company's oral liquid dosage forms include solutions, syrups, and suspensions.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20243/31/2024Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board, Managing Director Seelam N.Reddy 52 8/13/2021
Chief Financial Officer, Whole time Director Seelam K.Reddy 32 9/8/2021
Compliance Officer, Company Secretary NamrathaNagla 3/19/2024 3/19/2024
4 additional Officers and Directors records available in full report.

General Information
Outstanding Shares: 10,000,000 (As of 9/30/2024)
Stock Exchange: BOM
Fax Number: +91 4024036379


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, March 28, 2025